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Generation of pure lymphatic 
endothelial cells from human 
pluripotent stem cells and their 
therapeutic effects on wound 
repair
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Woansang Kim1, Yong Heui Jeon1, Eugine Lee1 & Young-sup Yoon1,3
Human pluripotent stem cells (hPSCs) have emerged as an important source for cell therapy. 
However, to date, no studies demonstrated generation of purified hPSC-derived lymphatic 
endothelial cells (LECs) and tested their therapeutic potential in disease models. Here we sought 
to differentiate hPSCs into the LEC lineage, purify them with LEC markers, and evaluate their 
therapeutic effects. We found that an OP9-assisted culture system reinforced by addition of VEGF-A, 
VEGF-C, and EGF most efficiently generated LECs, which were then isolated via FACS-sorting 
with LYVE-1 and PODOPLANIN. These hPSC-derived LYVE-1+PODOPLANIN+cells showed a pure 
committed LEC phenotype, formed new lymphatic vessels, and expressed lymphangiogenic factors 
at high levels. These hPSC-derived LECs enhanced wound healing through lymphangiogenesis and 
lymphvasculogenesis. Here we report, for the first time, that LECs can be selectively isolated from 
differentiating hPSCs, and that these cells are potent for lymphatic vessel formation in vivo and 
wound healing. This system and the purified hPSC-derived LECs can serve as a new platform for 
studying LEC development as well as for cell therapy.
Lymphatic vessels play an important role in tissue fluid homeostasis and immune surveillance, and 
thus dysfunctions in lymphatic vessels lead to the development of diseases such as lymphedema and 
tumors. Despite a continuous increase in lymphatic disorders, current therapeutic options for modify-
ing lymphatic pathophysiology are very limited. Recent progress in the field of lymphatic development 
has enhanced our understanding of molecular regulation of lymphatic vessel formation. In developing 
mouse embryos, LECs differentiate from a subpopulation of the endothelial cells of the cardinal vein and 
subsequently form the mature lymphatic vasculature with coordinated expression of SOX-18, PROX-1, 
LYVE-1, VEGFR3/VEGFC and PODOPLANIN1–6. More recently, attempts have been made to develop 
in vitro lymphatic differentiation systems using embryonic stem cells (ESCs) to establish a model system 
to investigate lymphatic vascular differentiation and to obtain a targeted cell population for therapeutic 
application. In addition, the discovery of induced pluripotent stem cells (iPSCs) has increased interest 
in using hPSCs, i.e., human embryonic stem cells (hESCs) and human induced pluripotent stem cells 
(hiPSCs), for cell therapy7–11.
1Division of Cardiology, Department of Medicine. 2Department of Pediatrics, Emory University School of Medicine, 
Atlanta, GA, 30322, USA. 3Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, 
Korea. *These authors contributed equally to this work. Correspondence and requests for materials should be 
addressed to Y-s.Y. (email: yyoon5@emory)
received: 06 January 2015
Accepted: 12 May 2015
Published: 12 June 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:11019 | DOi: 10.1038/srep11019
Studies have reported the feasibility of lymphatic endothelial lineage differentiation from mouse 
pluripotent stem cells (mPSCs). Liersch et al.12 demonstrated that initial emergence of cells with a LEC 
phenotype can be detected in embryoid bodies (EBs) at day 18 of spontaneous differentiation of mESCs. 
Kreuger et al.13 also showed that mESCs which were differentiated through EBs for 4 days and further 
cultured on type I collagen-coated plates expressed lymphatic markers. Although these studies have 
shown lymphatic endothelial differentiation characteristics of mESCs or miPSCs, they did not show 
detailed expression kinetics of LEC development or to confirm the identity of the PSC-derived cells as 
LECs in vivo. To date, no studies were reported regarding the in vivo behavior and therapeutic potential 
of hPSC-derived LECs.
A very common, but not widely known as lymphatic-related, disorder is skin wound. Wound healing 
is a complex process including coagulation, inflammation involving recruitment of inflammatory cells 
into the injured sites, and formation of granulation tissue with angiogenesis and lymphangiogenesis, 
followed by a remodeling process14. Impaired wound healing often becomes a serious complication in 
several diseases including diabetes. Recent studies have shown the importance of lymphatic vessel regen-
eration in wound healing. In cutaneous wound healing models of pig and mouse, VEGFR3-expressing 
lymphatic vessels were found in the granulation tissue followed by regression at later stages15,16. VEGFC, a 
ligand for VEGFR3, was increased in response to tissue injury17. While augmented expression of VEGFC 
can significantly promote wound healing as well as lymphangiogenesis, inhibiting VEGFC or another 
VEGFR3 ligand, VEGFD, leads to delayed recovery of wound17. Furthermore, macrophages derived from 
diabetic mice failed to improve wound repair, but upon activation with IL-1β promoted the recovery of 
the tissue injury with enhanced lymphatic regeneration, suggesting a critical role of lymphatic vessels 
in wound healing18. Despite this emerging knowledge of the importance of lymphatic vessels in wound 
healing, there are no studies available regarding the effects of stem cell therapy targeting lymphatic neo-
vascularization on wound repair.
In this study, we for the first time developed an efficient culture system to differentiate hESCs and 
hiPSCs into the lymphatic endothelial lineage and isolated LYVE-1+PODOPLANIN+cells as functional 
LECs. Furthermore, we demonstrated the contribution of these hPSC-derived LECs to in vivo lymphatic 
vascular commitment and their therapeutic potential in wound healing.
Results
Generation of cells expressing lymphatic markers from hESCs and hiPSCs. Since no studies 
have demonstrated generation of pure LECs from human pluripotent stem cells (hPSCs), we first sought 
to establish an efficient LEC differentiation system by trying three different culture conditions: sponta-
neous differentiation through EB formation, co-culture with OP9 cells, and a feeder-free culture with 
gelatin for lymphatic endothelial differentiation of hESC lines (H1 and H9) and hiPSCs (BJ1)19. First, the 
pluripotent cells were induced to form EBs and cultured under suspension conditions for 30 days. To 
determine whether hESCs were differentiated into LECs, we performed gene expression analysis with an 
emphasis on the expression of key LEC markers such as PROX1, LYVE1, VEGFR3 and PODOPLANIN. 
We found that hESCs (H1 and H9) began to express the LEC markers at day 7, peaked around day 20, 
and maintained expression up to day 30 (Fig. 1a). SOX18 and COUP-TFII, markers for early lymphatic 
endothelial cell specification, were also expressed in EB to D30 (see Supplementary Fig. S1 online). A 
similar expression pattern was observed in hiPSCs (BJ1, Fig.  1a) and in another hiPSC line that we 
generated from human dermal fibroblasts (hiPS-E1 line, data not shown). Interestingly, gene expression 
analysis revealed that expression of PROX1, LYVE1, and CD31 were significantly lower in H1 than in 
H9, suggesting variable differentiation potential between hESC lines20. In addition, we observed that the 
kinetics of LEC gene expression differed slightly between hESCs and hiPSCs, indicating intrinsic varia-
tion in differentiation characteristics of these cells21.
Next, we used a combination of lymphangiogenic cytokines and OP9 cells as a feeder layer for lym-
phatic endothelial differentiation22,23. EBs differentiated for 7 days under suspension conditions were sub-
sequently cultured on OP9 cells for an additional 30 days with VEGF-A, VEGF-C and EGF13,24,25. EGF 
was added to prevent cell death and augment cell proliferation. Overall, this culture condition induced 
expression of the LEC markers in all hESC and hiPSC lines at higher levels than spontaneous differenti-
ation (Figs 1a,b). Compared to the spontaneous differentiation system, LYVE1 and VEGFR3 expression 
were more highly detected in BJ1, and PODOPLANIN expression was 3- to 15-fold higher in H9 and BJ1 
under these co-culture conditions. OP9 cells did not express LEC markers (see Supplementary Fig. S2 
online). Together, these data indicate that a culture system using OP9 cells, lymphangiogenic cytokines, 
and EGF can induce lymphatic endothelial differentiation from hESCs and hiPSCs to a greater extent 
than spontaneous differentiation, and furthermore suggest that this system can reduce variation of lym-
phatic endothelial differentiation capacity between human pluripotent cell lines.
Finally, we tried a feeder-free system for LEC differentiation in which the cells were cultured onto 
gelatin with the same lymphatic growth factors and EGF. However, this condition resulted in lower effi-
ciency for LEC differentiation and higher cell death compared to the OP9 cell assisted culture system 
(data not shown). Collectively, our results clearly indicated the successful differentiation of hPSCs into 
the LEC lineage.
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Characterization of hPSC-derived LECs. To further characterize the identity of the cells derived 
from hESCs (H1 and H9) and hiPSCs (BJ1), we investigated whether the differentiated cells expressed 
LEC markers at the protein level with proper localization. In LECs, PROX-1, a transcription factor, 
is expressed in the nucleus, whereas LYVE-1, VEGFR3 and PODOPLANIN are localized in the cell 
membrane. As expected, immunostaining results showed (Fig.  2a) that while PROX-1 was exclusively 
localized in the nuclei of the differentiated cells, LYVE-1, VEGFR3 and PODOPLANIN were found 
Figure 1. Differentiation of hESCs (H1 and H9) and hiPSCs (BJ1) into the LEC lineage. (a) qRT-PCR 
analyses of in vitro differentiated H1, H9 and BJ1 cells through EB formation. N = 9 per group. *P < 0.05 vs. 
H1. (b) qRT-PCR analyses of in vitro differentiated H1, H9 and BJ1 cells on OP9 cells with lymphangiogenic 
cytokines. EBs differentiated for 7 days in suspension culture were replated on OP9 cells, further cultured for 
an additional 30 days with VEGF-A, -C and EGF, and subjected to qRT-PCR. N = 9 per group. *P < 0.05 vs. 
EB. UD: Undifferentiated hPSCs, POD: PODOPLANIN.
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Figure 2. Immunocytochemistry showing expression of LEC markers in the differentiated hESCs and 
hiPSCs. The pluripotent stem cells differentiated in suspension culture were subsequently cultured for 
10 to 15 days under the co-culture conditions. (a) Single LEC marker staining for LYVE-1, VEGFR3, or 
PODOPLANIN (POD). DAPI: blue. (b-d) Double LEC marker staining LYVE-1 and PROX-1 (b), VEGFR-3 
and PODOPLANIN (c), and PODOPLANIN and LYVE-1 (d) in H9-derived LECs. (e) Triple LEC marker 
staining LYVE-1, PODOPLANIIN, PROX-1 in H9-derived LECs. Arrows indicate the representative cells 
stained positive for two or three LEC markers as labeled.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:11019 | DOi: 10.1038/srep11019
in cell membranes, confirming correct localization of the key LEC markers in the differentiated cells. 
We also confirmed co-expression of double or triple LEC markers in differentiating cells (Figs  2b–e, 
Supplementary Fig. S3 and S4 online).
Next, we further examined the lymphatic endothelial differentiation of hESCs and hiPSCs with FACS 
analysis (Fig.  3). FACS analysis of H1 and BJ1-derived cells showed that after 14 days of co-culture 
with OP9 cells and lymphangiogenic growth factors, about 40–70% of these cells expressed PROX-1, 
LYVE-1 or PODOPLANIN, and about 10–15% expressed VEGFR3 (Figs 3a,b). Cells double-positive for 
Figure 3. FACS analyses for multiple LEC marker expression in differentiated hESCs and hiPSCs. 
FACS analyses were performed with H1 and BJ1 cells differentiated under the co-culture conditions for 7 
and 14 days. (a, b) Single LEC marker staining for H1 (a) and BJ1 (b). (c, d) Quadruple staining with LEC 
markers for H1 (c) and BJ1 (d). LYVE-1+POD+and LYVE-1−POD− cells were re-plotted for both VEGFR-3 
and PROX-1. (e) Bar graph for average percentage of differentiated H1 and BJ1 cells positive for four LEC 
markers. Number in each box of A through D represents percentage of positive cells of each indicated 
protein. N = 3, POD: PODOPLANIN.
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LYVE-1 and PODOPLANIN, VEGFR3 and PODOPLANIN, or LYVE-1 and VEGFR3 were observed 
at 10–50% at day 14 (data not shown). Next, we used the four LEC markers for FACS to further verify 
the identity of the cells, and found that about 10% of the differentiated cells at day 14 expressed all 
four LEC markers (Figs  3c–e), suggesting the LEC identity of differentiated H1 and BJ1 cells in our 
culture system. Since macrophages can also express LYVE-1 or PODOPLANIN 26,27, we also performed 
flow cytometry with CD14, a marker for human monocyte-macrophage lineage cells and found that 
virtually no LYVE-1+PODOPLANIN+cells were positive for CD14, indicating that these cells were not 
monocyte-macrophage lineage cells (see Supplementary Fig. S5 online). It is of note that under these 
culture conditions, the lymphatic endothelial phenotype was effectively maintained and the number of 
these cells increased for more than two weeks. We conclude that this culture system can effectively dif-
ferentiate hESCs and hiPSCs into the LEC lineage.
LYVE-1+PODOPLANIN+cells differentiated from hPSCs contribute to lymphatic vessel for-
mation. To validate the identity and functionality of the lymphatic endothelially committed cells iso-
lated from hESCs and hiPSCs differentiated under our culture conditions, we performed a series of in 
vitro and in vivo studies. In vivo behavior of lymphatic-endothelially differentiated ESCs or iPSCs has 
not been previously reported for human or mouse cells12,13,25,28. As PROX-1 is a nuclear protein, which 
is not suitable for cell sorting experiments without affecting cell viability, we took advantage of the two 
surface markers of LECs, LYVE-1 and PODOPLANIN to enrich LEC lineages from differentiated hPSCs. 
First, we tested in vitro activities of hESC- or hiPSC-derived LECs using a tube formation assay. Cells 
positive for both LYVE-1 and PODOPLANIN were isolated by FACS from differentiating H1 and BJ1 
cells at day 14, labeled with a red fluorescent dye, CM-DiI29, and subjected to tube formation assay. As 
shown in Supplementary Fig. S6, the sorted cells readily formed tube-like structures. Further, the LYVE-
1+PODOPLANIN+cells were able to incorporate into the tubular structure upon co-culture with hLECs in 
a Matrigel tube formation assay (Fig. 4a). Next, to determine the vasculogenic potential of hPSC-derived 
LECs in vivo, we injected the sorted cells into an ear wound model in which lymphatic vessel growth 
occurs18,30, harvested the tissues at 2 weeks, and conducted immunohistochemistry with frozen sec-
tions. A confocal microscopic examination of the stained sections with three-dimensional reconstruction 
demonstrated that the injected LYVE-1+PODOPLANIN+cells were incorporated into lymphatic vessels 
and expressed LEC markers (Fig. 4b). Finally, we determined lymphangiogenic gene expression in LYVE-
1+PODOPLANIN+cells. We measured mRNA expression of VEGFA, VEGFC, ANGPT1, ANGPT2, HGF, 
IGF, and FGF2 by qRT-PCR. Surprisingly, all the measured genes except ANGPT2 were more highly 
expressed in LYVE1+PODOPLANIN+cells compared to LYVE1-PODOPLANIN− cells and hLECs. These 
experiments clearly suggested that the LYVE-1+PODOPLANIN+cells have pro-lymphangiogenic proper-
ties and have the capability for lymphatic vessel formation as LECs in vivo.
LYVE-1+PODOPLANIN+cells differentiated from hPSCs promote wound healing through 
lymphatic neovascularization. Mounting evidence has suggested a crucial role for lymphatic vessel 
in wound repair15–18,31,32. Thus, we sought to determine whether the hPSC-derived LECs under our pro-
tocol can increase lymphatic neovascularization and enhance wound healing. To this end, we employed 
a skin wound model which is well known for its involvement with lymphatic vessel growth, and meas-
ured the wound area and lymphatic vascular density. LYVE-1+PODOPLANIN+cells were isolated by 
FACS at day 14 from differentiating H9 and BJ1 cells under the OP9 co-culture system and injected 
at four sites (2.5 × 104 cells/site) into the margins of the wound on the backs of nude mice. During 
the two-week follow-up, mice that had received the LYVE-1+PODOPLANIN+cells showed enhanced 
wound healing compared to the PBS or hLEC-injected mice, as demonstrated by decreased area of the 
wound (Fig. 5a,b). To elucidate the underlying cellular mechanisms for the LEC-mediated wound heal-
ing, we conducted immunohistochemical and gene expression analyses with the excised skin 2 weeks 
after the cell injection. As shown in Fig.  6a, the mice injected with the LYVE-1+PODOPLANIN+cells 
exhibited increased lymphatic vessel density compared to the control. Further, the injected cells were 
clearly incorporated into lymphatic vessels (Fig. 6b), suggesting lymphvasculogenesis. In addition, mice 
which received hPSC-derived LECs showed a significantly higher expression level of lymphangiogenic 
factors such as Vegfc, Vegfd, Vegfa, Angpt1, and Angpt2 (Fig.  6c). Together, these results indicate that 
hPSC-derived LECs can improve wound healing by promoting lymphatic neovascularization through 
both lymphvasculogenesis and lymphangiogenesis.
Discussion
This study documents for the first time that pure lymphatic endothelial lineage cells can be generated 
from differentiating hPSCs, and that these hPSC-derived LECs can effectively repair skin wound by 
inducing lymphangiogenesis and lymphvasculogenesis in vivo.
Several studies have reported lymphatic lineage differentiation from mouse13,28 or human PSCs33. 
However, no studies have successfully isolated functionally committed (or functional) lymphatic 
endothelial cells from mouse or human PSCs. As individual LEC markers are redundant in other cell 
types, confirming co-expression of multiple markers in a given cell is crucial to verify the identity of the 
PSC-derived LECs. Our study is the first to examine the comprehensive kinetics of multiple LEC marker 
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Figure 4. Contribution of LYVE-1+PODOPLANIN+cells derived from hESCs and hiPSCs to new 
lymphatic vessel formation. (a) In vitro tube formation assay. DiI-labeled LYVE-1+PODOPLANIN+cells 
(red) derived from hiESC (H1) cocultured with hLECs onto Matrigel for 12 hours, showing their 
incorporation into vascular structures consisting of hLECs. (b) DiI-labeled LYVE-1+PODOPLANIN+cells 
which were differentiated from H1 and BJ1 cells were injected into mice in an ear wound model. Two weeks 
later, tissues were harvested and subjected to immunohistochemistry with VEGFR3, PODOPLANIN, and 
LYVE-1 antibodies on frozen tissue sections. Confocal microscopic imaging revealed incorporation of injected 
cells (red) into lymphatic vascular structures and expression of PODOPLANIN and VEGFR3. (c) mRNA 
expression of the indicated lymphangiogenic genes in pre-sorted cells at day 14, LYVE1+PODOPLANIN+cells 
(BJ1-derived), LYVE1−PODOPLANIN−cells (BJ1-derived), and hLECs measured by qRT-PCR. Data were 
presented as relative mRNA expression to GAPDH. N = 3 to 4 per group. *P < 0.05. **P < 0.01.
www.nature.com/scientificreports/
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expression (i.e. SOX18, COUP-TFII, PROX1, LYVE1, VEGFR3, PODOPLANIN) during hPSC differen-
tiation, which is critical for studying the human LEC differentiation process as well as for expansion 
or selection of LECs or LEC precursors. We found that in EB-mediated spontaneous differentiation of 
hPSCs, LEC markers appeared by day 7 in culture, peaked around 20 days, and were expressed for at 
least 30 days, whereas previous studies using mESCs showed appearance of LEC markers only after more 
than 10 days in culture12,13. This earlier appearance of LEC markers in human cells may be due to the 
later developmental stage of hPSCs compared to mESCs34. Among three conditions that we tested, the 
co-culture system was more efficient for lymphatic endothelial differentiation than spontaneous differ-
entiation or a feeder-free system, and importantly, the lymphatic endothelial phenotype was effectively 
Figure 5. hPSC-derived LECs improve wound healing and increase lymphatic vessel formation. FACS-
sorted LYVE-1+PODOPLANIN+cells derived from hPSCs (H9 and BJ1) were injected into skin wound on 
the backs of nude mice. PBS and hLECs were used as controls. (a) Changes of the wound areas at indicated 
days after injection. (b) Quantitative analysis of wound areas. Y axis represents percent change of wound 
areas over original wound areas. Note that LYVE-1+PODOPLANIN+cells derived from both H9 and BJ1 
significantly promoted wound closure compared to the PBS- or hLEC-control. Two independent experiments 
were performed. N = 5 to 9 per group. *P < 0.05, **P < 0.01.
www.nature.com/scientificreports/
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Figure 6. Lymphvasculogenesis and lymphangiogenesis induced by hPSC-LECs in wound healing. 
(a) LYVE-1+PODOPLANIN+cells derived from hPSCs (H9 and BJ1) were injected into skin wound on 
the backs of nude mice. Lymphatic vascular density determined at day 14 after cell injection. Lymphatic 
vessels indicated by arrows (LYVE-1+) were significantly increased in mice injected with hPSC-derived 
LYVE-1+PODOPLANIN+cells compared to the hLEC-control. ***P < 0.001. Polyclonal rabbit anti-LYVE-1 
antibody was used for this staining. (b) LYVE-1+PODOPLANIN+cells labeled with CM-Dil were injected 
into the wounded skin in mice. Confocal microscopic imaging after staining tissues harvested at 2 weeks 
for VEGFR3 (green) showed incorporation of the injected cells (red) into lymphatic vessels. Arrows indicate 
co-localization of VEGFR3+lymphatic vessels with the injected cells. **P < 0.01. (c) Skin tissues from mice 
injected with hLEC, H9-LEC, or BJ1-LEC were subjected to qRT-PCR analyses. Graphs from 3 independent 
experiments are shown, *P < 0.05, **P < 0.01, ***P < 0.001, N = 3 per group.
www.nature.com/scientificreports/
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maintained with increasing numbers of target cells for 30 days, which is a definite advantage for various 
applications. Immunocytochemistry and FACS analysis confirmed co-expression of PROX1, VEGFR3, 
LYVE-1, and PODOPLANIN, but not CD14, a marker for the monocyte-macrophage lineage, indicating 
a LEC identity of the hPSC-derived cells in our culture system.
One of the important hurdles of hPSC-derived cells for therapy is their low yield. As there are no 
statistical data regarding the efficiency of lymphatic differentiation of hPSCs, we are unable to compare 
our system to other lymphatic endothelial differentiation systems. However, compared to the current 
published data regarding blood vascular endothelial lineage differentiation from human or mouse PSCs, 
which shows at most 10% of a single marker expression before cell sorting35–42, the efficiency of our 
system for lymphatic endothelial cell lineage differentiation was much higher, demonstrated by a single 
marker expression at more than 40% except for VEGFR3 (10–15%) and expression of the four LEC 
markers at ~10%. This high yield of differentiation makes this system appealing for testing in vivo behav-
ior and therapeutic potential of hPSC-derived LECs.
The LYVE-1+PODOPLANIN+cells isolated from these lymphatic-differentiated hPSCs demonstrated 
genuine characteristics of lymphatic endothelial cells as well as progenitor cell features. While fully 
mature hLECs do not possess therapeutic potential due to their low lymphvasculogenic and lymphangio-
genic activities, these purified hPSC-LECs showed such progenitor cell activities and were therapeutically 
effective. The purified hPSC-LECs expressed all representative LEC markers and were capable of forming 
tubes, which are typical characteristics of mature LECs. In addition, these hPSC-LECs possessed the 
capability of being incorporated into lymphatic vessels after transplanted in vivo suggesting lymphvascu-
logenic capability and have high pro-lymphangiogenic capacity. Moreover, when implanted into the skin 
wound, they were able to induce cutaneous lymphatic neovascularization and promote wound healing 
with concomitant increase in lymphangiogenic growth factors, indicating that the injected LECs could 
enhance new lymphatic vessel formation through lymphvasculogenesis and lymphangiogenesis. These 
findings strongly suggest therapeutic potential of the hPSC-derived LECs in treating diseases related to 
lymphatic dysfunction. In this regard, growing evidence has suggested that lymphatic vessels can play 
an important role in wound healing. Saaristo et al.17 have shown that VEGFC promotes wound healing 
with concomitant enhancement of lymphangiogenesis as well as angiogenesis in diabetic db/db mice. 
Maruyama et al.18 have reported that decreased numbers and activation of macrophages are responsible 
for reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. It was also 
shown that COMP-angiopoietin 1 significantly improved skin wound closure, accompanied by increased 
lymphatic vessel formation in diabetic db/db mice31. Inhibition of Notch signaling with Dll1 neutralizing 
antibodies was shown to impair lymphatic regeneration as well as wound closure32. While our study 
further confirmed that increased lymphatic vessels can promote wound healing, this is the first study to 
demonstrate that lymphatic vessel growth can be induced by provision of stem cell-derived LECs, high-
lighting the potential therapeutic utility of the cells generated by our newly developed protocol. Recent 
studies have suggested that enhanced lymphangiogenesis upon inflammation functions to resolve the 
tissue edema and facilitate recruitment of immune cells such as macrophages and dendritic cells43–45. 
Wound healing is a representative inflammatory model and optimal wound healing requires a balance 
between inflammatory cell infiltration and exit. Our data suggest that lymphatic vessel growth induced 
by hPSC-LEC implantation in the skin can increase drainage of tissue fluid and maintain the balance 
of inflammatory cells, thereby enhancing wound repair. While this study provides the proof of concept 
regarding the utility of hPSC-derived LECs in promoting wound healing, it should be validated further 
in wound healing associated to risk factors favoring wound.
In summary, we developed a novel culture-isolation system to efficiently generate lymphatic endothe-
lial lineage cells from hPSCs. Through this system, cells expressing multiple LEC markers such as PROX-
1, LYVE-1, VEGFR3 and PODOPLANIN, but not CD14, were generated at high yield, strongly arguing 
the LEC identity of the cells. Upon injection into a mouse model of wound, the FACS-sorted LYVE-
1+PODOPLANIN+cells from lymphatic-differentiated hPSCs were able to contribute to the newly devel-
oping lymphatic vessels and also promoted lymphatic neovascularization and wound repair. Together, 
this study for the first time reports the generation of functional LECs from hESCs and hiPSCs. This 
system could be used as an important platform for investigating human lymphatic vascular differentia-
tion or development and allow generation of lymphatic endothelial cells to be used for cell therapy for 
intractable wounds or lymphedema.
Methods
All animal protocols were reviewed and approved by the Emory University Institutional Animal Care and 
Use Committee and all animal procedures were performed in accordance with the approved guidelines 
and regulations.
Cell culture and hESC/iPSC differentiation. H1 and H9 (hESCs) and BJ1 (hiPSCs obtained from 
Dr. Daley)19 were maintained on mitomycin C-treated STO cells in ESC medium as described previ-
ously46,47. To induce spontaneous differentiation via EB formation, mechanically dissociated clumps of 
hESCs or hiPSCs were cultured in hESC medium without bFGF for the indicated days. For directed 
differentiation, EBs harvested at day 7 were replated on OP9 cells in 5% FBS/α -MEM supplemented with 
VEGF-A (50 ng/ml), VEGF-C (100 ng/ml) and EGF (10 ng/ml).
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Fluorescence activated cell sorting (FACS) and Magnetic activated cell sorting (MACS). EBs 
differentiated for 7 days under suspension conditions were further cultured on OP9 cells for an additional 
14 days. The resulting cells were stained with APC-conjugated sheep anti-human PODOPLANIN (R&D 
Systems) and biotinylated rabbit anti-human LYVE-1 (ReliaTech GmbH) followed by streptavidin-Alexa 
488 (Invitrogen), and then sorted with FACSVantageSE (BD). The purity of the sorting was approx-
imately 98%. For sorting of LYVE-1+PODOPLANIN+with magnetic-labeled cell separation system 
(MACS®), differentiated hPSCs were incubated with APC-conjugated sheep anti-human PODOPLANIN 
(R&D Systems) and biotinylated rabbit anti-human LYVE-1 (ReliaTech GmbH). After washing, the 
cell pellet was incubated with anti-APC and anti-Biotin Microbeads (Miltenyi Biotec) and subjected to 
MACS sorting (Miltenyi Biotec).
Wound healing model. hPSC-derived LYVE-1+PODOPLANIN+cells were isolated using magnetic 
columns (MACS®, Milteny Biotec). Full-thickness excisional skin wounds (8 mm) were created on the 
backs of male athymic nude mice, and PBS (100 μ l), LYVE-1+PODOPLANIN+cells (1 × 105) or hLECs 
(HMVEC-dLy-neo, Lonza) labeled with DiI were injected into the wound bed around the wound. The 
wound tissues, including a perimeter of 1 to 2 mm of normal skin tissue, were harvested for immunohis-
tochemistry at day 4, 7, or 14 after the injection. Wound closure was monitored at days 0, 2, 4, 6, 8 and 
12 and calculation of the area of the wound was performed with the NIH Image J analyzer.
Ear wound model. After shaving hairs and aseptic preparation, full-thickness excisional skin wounds 
were created on ears of the mice using 2-mm skin biopsy punches (Baker Cummins Dermatological, 
Livingston, NJ). hPSC-derived LYVE-1+PODOPLANIN+cells (1 × 105) labeled with DiI in 50 μ l PBS 
were then injected into and around the wound. Two weeks later, ear tissues were harvested, fixed with 
4% PFA, and sectioned for immunohistochemistry.
Matrigel® tube formation assay. Basement membrane matrix (Matrigel®, BD Biosciences) was 
added to 2-well chamber slides and solidified by incubation at 37 °C for 30 minutes. hPSC-derived LYVE-
1+PODOPLANIN+cells (2 × 104) were labeled with CM-DiI, plated with hLECs (HMVEC-dLy-neo, 
1 × 105, Lonza) onto Matrigel, and cultured under α -MEM medium containing 10% FBS, 1% nonessen-
tial amino acids, 0.1 mM β -mercaptoethanol, 4 ng/mL of FGF2, 10 ng/ml VEGF-A, 20 ng/mL of VEGF-C, 
and 10 ng/ml EGF, and incubated at 37 °C for 12 h. After removing the medium, 4% PFA was added for 
fixation. The tube structures were evaluated by microscopy.
Immunocytochemistry and Immunohistochemistry. Cells were fixed with 4% PFA for 30 min at 
4 °C. After washing with PBS, the cells were blocked with 5% serum and subjected to staining with primary 
antibodies followed by secondary antibodies. DAPI was used for nuclear staining and the cells were visu-
alized under a fluorescent microscope (Nikon). Primary antibodies: mouse anti-human PODOPLANIN 
D2-40 (Covance), rabbit anti-human PROX-1 (Abcam), rabbit biotin conjugated anti-human PROX-1 
(ReliaTech GmbH), rabbit anti-LYVE-1 (ReliaTech GmbH), and rabbit anti-VEGFR3 (Santa Cruz 
Biotechnology). The LYVE-1 and VEGFR3 antibodies have cross-reactivity to human, mouse, and rat. 
Secondary antibodies: FITC-conjugated goat anti-rabbit IgG, Cy3-conjugated goat anti-mouse IgG 
(Jackson Immunoresearch Laboratories), Alexa Fluor® 647 conjugated anti-mouse IgG, or Alexa Fluor® 
488 conjugated Streptavidin (Molecular Probes). For immunohistochemistry, samples frozen in OCT 
embedding medium (Sakura) were sectioned. The 6 to 30 μ m tissue sections were blocked with 3% nor-
mal goat serum in 0.1% Triton-X100 in phosphate-buffered saline (PBS) for 2 hours and were incubated 
overnight with primary antibodies followed by secondary antibodies at 4 °C. Images were taken with a 
LSM 510 Meta confocal laser scanning microscope (Carl Zeiss).
Flow cytometry. FACS staining and analysis were performed as previously described29. For 
four-marker staining, cells were incubated with Alexa488-conjugated rat anti-human PODOPLANIN 
(Biolegend), PE-conjugated mouse anti-human VEGFR3 (R&D system), and biotinylated rabbit 
anti-human LYVE-1 (ReliaTech GmbH) followed by streptavidin PE-Cy5 (BD Pharminogen). After 
washing, the cells were fixed/permeabilized (IC Fixation/Permeabilization buffer, eBioscience) and incu-
bated with goat anti-human PROX-1 (R&D Systems), followed by donkey APC-Cy7-conjugated anti-goat 
IgG (Santa cruz). The resulting cells were analyzed on a C6 Flow Cytometer (Accuri Cytometers Inc) 
and data were evaluated with CFlow software. For single marker staining, we used the same antibodies 
as described.
Quantitative RT-PCR. Total RNA extraction and cDNA synthesis was performed as previously 
described48. Briefly, total RNA was extracted from cells or tissues using the RNeasy kit (Qiagen) according 
to the manufacturer’s instructions. Subsequently, extracted RNA was reverse-transcribed using Taqman 
Reverse Transcription Reagents (Applied Biosystems) according to the manufacturer’s instructions. The 
synthesized cDNA was subjected to qPCR using specific primers and probes. Quantitative assessment of 
RNA levels was performed using an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). 
Relative mRNA expression normalized to GAPDH expression was calculated by using the formula 
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Relative Expression Level = 2−ΔCT, where Δ CT = CT gene of interest – CT GAPDH. The primers and 
probes were designed using Primer Express 3.0 (Applied Biosystems) and listed in Supplementary infor-
mation, Table S1.
Statistical analyses. All results were expressed as mean ± SEM. Statistical analysis was performed 
by an unpaired Student’s t-test for comparisons between two groups and two-way repeated measures 
ANOVA, and Bonferroni-post comparison test was used for the results in Fig.  5b comparing three 
groups. P value < 0.05 was considered to denote statistical significance.
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